NCT04523064View on ClinicalTrials.gov

POST-CABGDM: Empagliflozin in Perioperative CABG

PHASE4CompletedINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

September 22, 2020

Primary Completion Date

January 30, 2024

Study Completion Date

January 30, 2024

Conditions
Diabetes Mellitus, Type 2Coronary Artery DiseaseCoronary Artery Bypass SurgeryAcute Kidney Injury
Interventions
DRUG

Empagliflozin 25 MG

Patients with diabetes waiting for surgery will receive empagliflozin for at least three months.

Trial Locations (1)

05403010

University of Sao Paulo Medical School - The Heart Institute, São Paulo

All Listed Sponsors
lead

University of Sao Paulo General Hospital

OTHER

NCT04523064 - POST-CABGDM: Empagliflozin in Perioperative CABG | Biotech Hunter | Biotech Hunter